Skip to content

Clinical trials of mesenchymal stem cells for the treatment of pneumonitis caused by novel coronavirus pneumonia (COVID-19)

Clinical trials of mesenchymal stem cells for the treatment of pneumonitis caused by novel coronavirus (COVID-19)

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000029990
Enrollment
Unknown
Registered
2020-02-18
Start date
2020-01-30
Completion date
Unknown
Last updated
2020-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

pneumonitis caused by novel coronavirus

Interventions

Sponsors

Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Male or female, 18-95 years old; 2. 2019 new coronavirus nucleic acid test positive; 3. Diagnosed as moderate to severe cases of new coronavirus pneumonia in 2019, which meets the following clinical manifestations: 4. With fever and respiratory symptoms, imaging shows pneumonia; 5. A severe case diagnosed with 2019 new coronavirus pneumonia, that is, any of the following: (1) Increased breathing rate (>=30 beats / min), difficulty breathing, cyanosis of lips; (2) In the resting state, it means that oxygen saturation <=93%; or blood oxygen drops rapidly; (3) Arterial blood oxygen partial pressure (PaO2) / oxygen concentration (FiO2) <=300mmHg (1mmHg = 0.133kPa); 6. I or the authorized agent signed the informed consent form; 7. Agree to collect clinical samples.

Exclusion criteria

Exclusion criteria: 1. Malignant disease in the past five years; 2. The clinical prediction is that there is no hope for survival, only cases of hospice care, or cases of deep coma that do not respond to supportive treatment measures within three hours of admission; 3. Subjects who are participating in other clinical trials or within 3 months; 4. Cases of very severe shock and respiratory failure.

Design outcomes

Primary

MeasureTime frame
Improved respiratory system function (blood oxygen saturation) recovery time;

Countries

China

Contacts

Public ContactRobert Chunhua Zhao/Ronghua Jin

institute of basic medicine, Chinese Academy of medical sciences

zhaochunhua@vip.163.com+86 010-65125311

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026